The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26189010 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Oscar René Zambrano-Vásquez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana, Mexico City 14387, Mexico. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Metformin, Fatty Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Nacional de Cardiología Ignacio Chávez.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses several cardiometabolic risk factors (obesity, insulin resistance, diabetes, and dyslipidemia), in addition to hepatic steatosis. Therefore, treatment is often challenging and frequently involves polypharmacy. This study investigated whether the combination of empagliflozin/metformin improves MASLD disease outcomes in an experimental model of metabolic syndrome (MS). To evaluate the efficacy of the empagliflozin/metformin (12.5/850 mg/kg/day/30 days) combination, male Wistar rats (200–220 g) were fed a Western-type diet and sugary drink to induce MS. Biochemical parameters, markers of liver damage, oxidative stress, and histopathological analysis were assessed. Also, the expression of transcription factors associated with carbohydrate and lipid metabolism and the modulation of oxidative stress were assessed. The analyses were performed with the combination and with the drugs independently. The combination empagliflozin/metformin decreased body weight, plasma triglycerides, and total cholesterol levels, while improving fasting blood glucose, oral glucose tolerance test, and plasma HDL-cholesterol levels. Additionally, it prevented hepatic hypertrophy, liver damage at both biochemical and histological levels, and intrahepatic lipid accumulation. The combination also demonstrated a significantly greater effect in improving mitochondrial function and reducing oxidative stress by modulating the Nrf2-mediated pathway. The empagliflozin/metformin combination therapy mitigates MASLD progression, likely by improving liver and mitochondrial function, and attenuating oxidative stress. Notably, co-therapy shows greater beneficial effects than single treatments. This protective effect appears to involve modulation of key transcription factors regulating lipid and carbohydrate metabolism, as well as influencing endogenous antioxidant defenses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana, Mexico City 14387, Mexico.
- Departamento de Fisiopatología Cardio-Renal, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
- Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.
- Department of Biological Systems, Universidad Autónoma Metropolitana-Xochimilco, Mexico City 04960, Mexico.
- Department of Natural Sciences, Universidad Autónoma Metropolitana-Cuajimalpa, Mexico City 05348, Mexico.
- Departamento de Farmacología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
ORCID-Profile: Oscar René Zambrano-Vásquez, Juan Carlos Cabrera-Angeles, Ana Lilia Hernández-Alba, Jorge Ismael Castañeda-Sánchez, Elena Aréchaga-Ocampo, Constanza Estefanía Martínez-Olivares, Rogelio Hernández-Pando, Horacio Osorio-Alonso
Förderung
- Instituto Nacional de Cardiología Ignacio Chávez
Zitieren
APA
Zambrano-Vásquez, O. R., Cortes-Camacho, F., Cabrera-Angeles, J. C., Hernández-Alba, A. L., García-Arroyo, F. E., Castañeda-Sánchez, J. I., Aréchaga-Ocampo, E., Aparicio-Trejo, O. E., Valle-Mondragón, L. D., Martínez-Olivares, C. E., Hernández-Pando, R., Sánchez-Lozada, L. G., & Osorio-Alonso, H. (2025). The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26189010
Vancouver
Zambrano-Vásquez OR, Cortes-Camacho F, Cabrera-Angeles JC, Hernández-Alba AL, García-Arroyo FE, Castañeda-Sánchez JI, et al. The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26189010
BibTeX
@article{ZambranoVsquez2025,
author = {Zambrano-Vásquez, Oscar René and Cortes-Camacho, Fernando and Cabrera-Angeles, Juan Carlos and Hernández-Alba, Ana Lilia and García-Arroyo, Fernando Enrique and Castañeda-Sánchez, Jorge Ismael and Aréchaga-Ocampo, Elena and Aparicio-Trejo, Omar Emiliano and Valle-Mondragón, Leonardo Del and Martínez-Olivares, Constanza Estefanía and Hernández-Pando, Rogelio and Sánchez-Lozada, Laura Gabriela and Osorio-Alonso, Horacio},
title = {The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26189010}
}
EUVIMED